亚洲欧美日一线高本道_在线播放中文字幕无码免费_国产精品色午夜小视频_国产成人MV在线观看


管理培訓搜索
18318889481 13681114876

合規(guī)
| 美國最高法院拒絕澄清虛假索賠法的虛假標準當前您所在的位置:首頁 > 合規(guī) > 反洗錢中心 > 舞弊新聞

U.S. Supreme Court Declines to Clarify False Claims Act Falsity Standard

        The U.S. Supreme Court recently declined to address a circuit split regarding the standard for establishing that a statement material to a claim for payment is false under the False Claims Act (FCA); specifically, whether the FCA requires pleading and proof of an “objectively false statement,” or whether liability can be based on allegedly false opinions. While the Courts of Appeals have taken conflicting positions on these issues, the circuit split is not as deep as would appear and the variation in standards are likely to have a minimal impact on ultimate outcomes. Nevertheless, with these varying standards for establishing falsity, healthcare providers and government contractors should take proactive steps to ensure signed certifications pertinent to a claim reflect appropriate diligence and decision-making and convey reasonably and honestly held opinions.

 

        A plaintiff must allege and prove the following to prevail on an FCA claim: (1) a false statement, (2) made with the requisite scienter (or knowledge that it was false), (3) that was material, causing (4) the government to pay out money. The threshold issue here relates to the proof required to establish the first prong, that information in or material to a claim is actually false. Assessing whether an opinion conveyed in a relevant certification is reasonably held or is false, however, is inextricably tied to the assessment of the second element, whether the statement was made with the requisite knowledge of the fraudulent nature of the statement (and either deliberate ignorance or reckless indifference is sufficient to establish scienter in the FCA context).

 

        On February 22, 2021, the U.S. Supreme Court denied petitions for certiorari in two cases seeking review of opinions of the Third and Ninth Circuits in United States ex rel. Druding v. Care Alternatives, 952 F.3d 89, 97 (3d Cir. 2020), and United States ex rel. Winter v. Gardens Regional Hospital and Medical Center, 953 F.3d 1108, 1114 (9th Cir. 2020), respectively, regarding whether the FCA required proof of an “objective falsity” in a material statement to establish liability. Both cases involve allegations of healthcare fraud arising from false physician certifications, and the circuit opinions in those cases both address the “objective false statement” standard articulated by the Eleventh Circuit in United States v. AseraCare, Inc., 938 F.3d 1278 (11th Cir. 2019).

 

        In the AseraCare case, which involved allegations centering on purportedly false certifications that federal healthcare program beneficiaries were terminally ill and therefore eligible for hospice services, the Eleventh Circuit held that to properly state a claim under the FCA, the plaintiff must demonstrate an objective falsity in the statement at issue, which is “something more than the mere difference of reasonable opinion.”

 

        In contrast, the Third Circuit in ex rel. Druding (another case centering on allegedly false terminal illness certifications) flatly rejected the AseraCare Court’s objective falsity standard for FCA claims. The Third Circuit reasoned that “clinical judgments” like other opinions, can “be ‘false’ for purposes of FCA liability.” The Care Alternatives Court further held that the objective falsity standard “improperly conflates the elements of scienter and falsity,” effectively reading the scienter requirement out of the statute: “objectivity speaks to the element of scienter, not falsity … the text and application of the FCA require that the elements of falsity and scienter be analyzed separately.”

 

        Similarly, the Ninth Circuit in ex rel. Winter (involving allegedly false certifications that hospitalization was medically necessary for federal healthcare program beneficiaries) rejected the argument “that only ‘objectively false’ statements can give rise to FCA liability.” The court noted that, “under the common law, a subjective opinion is fraudulent if it implies the existence of facts that do not exist or if it is not honestly held.” Despite concluding that a physician’s opinion with “no basis in fact can be fraudulent if expressed with scienter,” the Ninth Circuit claimed that their decision did not conflict with AseraCare. The Winter Court reasoned that the AseraCare objective falsity standard was limited to the fact specific and inherently speculative context of the “hospice-benefit provision at issue” (i.e., the forward-looking assessment that a patient was terminally ill and so likely had six months or less to live).

 

        With the Supreme Court declining to provide clarity, government contractors, healthcare entities, and other heavily regulated industries should take note of the ongoing legal uncertainty and potentially disparate levels of risk in different parts of the country. It is unclear to what extent, if any, that entities can rely on AseraCare and the objective falsity standard outside of the Eleventh Circuit (Alabama, Florida, and Georgia) and the hospice context.

 

        That said, the careful reading of the three circuit opinions shows that there is less to the circuit split than meets the eye: While the Eleventh Circuit did adopt an “objective falsity” standard that the Third and Ninth Circuits rejected, the AseraCare Court took pains to broadly define “objective falsity” to include not only patently false certifications containing forged or “rubber stamped” signatures, but also opinions that are not honestly held or reasonable. As such, even the Eleventh Circuit conceded that statements of opinion and clinical judgment can be false if they “disregard[] the patient’s underlying medical condition” and so are not necessarily immune from liability. Moreover, while the AseraCare Court held that a certifying physician’s state of mind must be considered when assessing falsity, and the Ninth and Third Circuits held that such an analysis should be conducted when evaluating scienter, the elements of falsity and knowledge are tightly intertwined: Whether an opinion was dishonestly or unreasonably held (and therefore false), and whether that opinion was conveyed with the knowledge that is was false, are closely related questions. That being the case, whether state of mind is assessed in determining both falsity and scienter, or just scienter, is not likely to affect the outcome of most cases.

 

        Companies should be conscious that a certifying official’s opinion may trigger FCA liability if it is not supported by evidence or if it is not reasonably or honestly held. The fact that a statement at issue may be an opinion or an expression of professional judgment will not automatically immunize the statement from liability, no matter which circuit the case is in. Healthcare providers and government contractors should therefore consider reviewing internal policies related to certifications that are material to a claim for payment. Companies are encouraged to be proactive in mitigating the risk of enforcement actions, including through the maintenance of a robust Governance, Risk, and Compliance (GRC) program and periodic audits of business processes to ensure certifications are supported by documentation in the clinical records or contract files, and made in an environment conducive to considered judgment and free from inappropriate pressure. These proactive mitigating steps are especially important where noncompliance includes the potential for treble damages and per invoice penalties under the FCA.

來源:ACFE官網 

TESG
企業(yè)概況
聯(lián)系我們
專家顧問
企業(yè)文化
黨風建設
核心團隊
資質榮譽
合規(guī)監(jiān)管
部門職責
轉創(chuàng)中國
加入轉創(chuàng)
經濟合作
智庫專家
質量保證
咨詢流程
聯(lián)系我們
咨詢
IPO咨詢
投融資咨詢
會計服務
績效管理
審計和風險控制
競爭戰(zhàn)略
審計與鑒證、估價
企業(yè)管理咨詢
人力資源戰(zhàn)略與規(guī)劃
融資與并購財務顧問服務
投資銀行
企業(yè)文化建設
財務交易咨詢
資本市場及會計咨詢服務
創(chuàng)業(yè)與私營企業(yè)服務
公司治理、合規(guī)與反舞弊
國企改革
價值辦公室
集團管控
家族企業(yè)管理
服務
數據分析
資信評估
投資咨詢
風險及控制服務
管理咨詢
轉型升級服務
可行性研究咨詢服務
民企與私人客戶服務
解決方案
內控
稅收內部控制
稅收風險管理
內控管理師
內部控制咨詢
信用研究
信用法制中心
風險與內控咨詢
無形資產內控
企業(yè)內控審計
內部控制服務
內部控制評價
內部控制體系建設
內部控制智庫
上市公司內控
上市公司獨立董事
投行
M&A
資本市場
SPAC
科創(chuàng)板
金融信息庫
IPO咨詢
北交所
ASX
SGX
HKEX
金融服務咨詢
信用評級
上海證券交易所
NYSE
深圳證券交易所
審計
審計資料下載
法證會計
審計事務
審計及鑒證服務
審計咨詢
反舞弊中心
內部控制審計
內部審計咨詢
國際審計
合規(guī)
銀行合規(guī)專題
合規(guī)管理建設年
海關與全球貿易合規(guī)
數據合規(guī)專題
反腐敗中心
反壟斷合規(guī)
反舞弊中心
國際制裁
企業(yè)合規(guī)中心
信用合規(guī)專題
證券合規(guī)專題
合規(guī)中心
金融合規(guī)服務
反洗錢中心
全球金融犯罪評論
行業(yè)
新基建
文化、體育和娛樂業(yè)
電信、媒體和技術(TMT)
投城交通事業(yè)部
房地產建筑工程
醫(yī)療衛(wèi)生和社會服務
可持續(xù)發(fā)展與環(huán)保
全球基礎材料
大消費事業(yè)部
金融服務業(yè)
化學工程與工業(yè)
一帶一路
智慧生活與消費物聯(lián)
數字經濟發(fā)展與檢測
食品開發(fā)與營養(yǎng)
先進制造事業(yè)部
能源資源與電力
消費與工業(yè)產品
運輸與物流
酒店旅游餐飲
科學研究與技術服務
政府及公共事務
化妝品與個人護理
一二三產融合
生物醫(yī)藥與大健康
新能源汽車與安全產業(yè)
法律
法律信息庫
稅法與涉稅服務
數字法治與網絡安全
勞動與人力資源法律
金融與資本市場法律
司法研究所
公司法專題
私募股權與投資基金
債務重組與清算/破產
轉創(chuàng)國際法律事務所
轉創(chuàng)法信事務所
財稅
法務會計
管理會計案例
決策的財務支持
家族資產和財富傳承
財稅法案例庫
資產評估
財稅信息庫
會計準則
財務研究所
財政稅收
會計研究所
財稅實務
投資咨詢
財務管理咨詢
審計事務
管理
轉創(chuàng)智庫
金融研究所
企業(yè)管理研究所
中國企業(yè)國際化發(fā)展
經濟與產業(yè)研究
公司治理
氣候變化與可持續(xù)
ESG中心
管理咨詢
轉創(chuàng)
咨詢業(yè)數據庫
轉創(chuàng)網校
生物醫(yī)藥信息庫
建筑工程庫
轉創(chuàng)首都
轉創(chuàng)教育
轉創(chuàng)國際廣東 官網
科研創(chuàng)服
中國轉創(chuàng)雜志社
創(chuàng)新創(chuàng)業(yè)
轉型升級
技術轉移中心
轉創(chuàng)中國
中外
粵港澳大灣區(qū)
中國-東盟
一帶一路
澳大利亞
俄羅斯
新加坡
英國
加拿大
新西蘭
香港
美國
中非平臺
開曼群島
法國
歐洲聯(lián)盟
印度
北美洲
18318889481 13681114876
在線QQ
在線留言
返回首頁
返回頂部
留言板
發(fā)送